|
Evaluate perceptions of Puricase® (PEG-uricase), a new therapy for refractory gout.
Understand facilitators and barriers to Puricase’s use in the context of allopurinol’s widespread use and febuxostat’s journey to FDA approval
Determine impact of potential weaknesses of Puricase
Products Highlighted:
Puricase®, Savient Pharmaceuticals
Allopurinol, (Multiple)
Febuxostat, TAP Pharmaceutical Products Inc.
Topics:
Use of gout treatments
Awareness and perceptions of gout treatments
Strengths and weaknesses of gout treatments
Gout treatment trends
Quotes:
“I use…most frequently. I also use…occasional use of….”
“But this agent lowers….and it would be wonderful if…was not an issue.”
“XXX is further along in trials. It also works in a similar fashion to…., people may embrace it easier because people know and are comfortable with...”
Screening Criteria:
US and European rheumatologists (n=9)
Treating high volume of patients with hyperuricemia and gout
Dispensing a high number of allopurinol prescriptions across the previous 6 months
Affiliated with academic medical centers/centers of excellence
Have published research about gout
Representative Institutions:
Emory University
University of Pittsburgh Medical Center
New England Baptist Hospital
Temple University
Downstate Medical Center
Hospital for Special Surgery
Kings College Hospital
University of Washington
University of Alabama
Veterans Affairs Hospital | 
Public Research Library
about us 